Back to Journals » International Journal of Nanomedicine » Volume 12

Anti-MUC1 nano-aptamers for triple-negative breast cancer imaging by single-photon emission computed tomography in inducted animals: initial considerations

Authors Santos do Carmo F, Ricci-Junior E, Cerqueira-Coutinho C, Albernaz MS, Bernardes ES, Missailidis S, Santos-Oliveira R

Received 29 July 2016

Accepted for publication 12 October 2016

Published 19 December 2016 Volume 2017:12 Pages 53—60


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Thomas Webster

Fagner Santos do Carmo,1,2 Eduardo Ricci-Junior,3 Cristal Cerqueira-Coutinho,4 Marta de Souza Albernaz,1,5 Emerson Soares Bernardes,6 Sotiris Missailidis,7 Ralph Santos-Oliveira2

1Rio de Janeiro State University, Biology Institute Roberto Alcantara Gomes, 2Brazilian Nuclear Energy Commission, Nuclear Engineering Institute, 3Federal University of Rio de Janeiro, Faculty of Pharmacy, 4Federal University of Rio de Janeiro, Institute of Macromolecules Eloisa Mano, 5University Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro, 6Instituto de Pesquisas Energéticas e Nucleares, Centro de Radiofarmácia, São Paulo, 7Institute of Technology in Immunobiologics Bio-Manguinhos, Oswaldo Cruz Foundation (Fiocruz), Rio de Janeiro, Brazil

Abstract: The early and specific detection of tumors remains a barrier in oncology, especially in cases such as the triple-negative breast cancer (TNBC). To address this gap, aptamers have found an important application in the recognition of tumor biomarkers such as mucin 1 (MUC1). However, there are still some difficulties in the use of aptamer, as their rapid biological clearance makes their use as drugs limited. In this study, the anti-MUC1 aptamer was used as a drug delivery system (DDS) for a radioactive polymeric nanoparticle (NP) in the imaging of TNBCs. Thus, poly(lactic-co-glycolic acid) NPs loaded with the anti-MUC1 aptamer and labeled with technetium-99m were used for a biodistribution study and imaging of TNBC. The results confirmed that the NP was successfully obtained, with a mean size of 262 nm, according to the dynamic light scattering data. The biodistribution assay in induced animal models with TNBC showed that although there was a high capture by intestine (>30%), the DDS developed had a high tumor uptake (5%) and with great in vivo imaging properties, corroborating the possibility of use of this DDS as an imaging drug for TNBC.

Keywords: aptamer, cancer control, imaging, nuclear medicine, radiopharmacy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]